Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

John M. Timmerman, Julie M. Vose, Debra K. Czerwinski, Wen Kai Weng, Diane Ingolia, Martha Mayo, Dan W. Denney, Ronald Levy

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Tumor-specific variable regions of the clonal immunoglobulin (idiotype, Id) expressed by B cell non-Hodgkin lymphoma (NHL) can be targeted by active immunotherapy. We conducted a phase I/II trial to determine the safety and immunogenicity of a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax® personalised immunotherapy) in 22 patients with follicular NHL in first remission after chemotherapy. Subjects received five subcutaneous immunisations with MyVax® plus locally administered granulocyte-macrophage colony-stimulating factor (GM-CSF). Among 21 evaluable patients, 62% mounted Id-specific immune responses. Evoked anti-Id antibodies recognised both recombinant Id and native Id, and could specifically stain autologous tumor cells. At median follow-up of more than 6 years, median progression-free survival is 38 months. Immunisation of follicular lymphoma patients with MyVax® Id-KLH is safe and patients often mount tumor-specific immune responses. These results form the basis of a pivotal phase 3 trial of MyVax® in follicular NHL.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalLeukemia and Lymphoma
Volume50
Issue number1
DOIs
StatePublished - 2009

Keywords

  • Immunotherapeutic approaches
  • Immunotherapy
  • Lymphoma and Hodgkin disease
  • Neoplasia
  • Vaccines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this